Pacts In Medtech, July/August 2016
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
You may also be interested in...
New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech
Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.
Deals In Depth: January 2021
BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.
Financing: 2020 Ends On A High Note For Medtech
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: